AIM IMMUNOTECH INC (AIM) Stock Price & Overview
NYSEARCA:AIM • US00901B3033
Current stock price
The current stock price of AIM is 0.9412 USD. Today AIM is up by 2.53%. In the past month the price decreased by -18.04%. In the past year, price increased by 327.4%.
AIM Key Statistics
- Market Cap
- 3.972M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -20.24
- Dividend Yield
- N/A
AIM Stock Performance
AIM Stock Chart
AIM Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AIM. When comparing the yearly performance of all stocks, AIM is one of the better performing stocks in the market, outperforming 98.35% of all stocks.
AIM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AIM. AIM has a bad profitability rating. Also its financial health evaluation is rather negative.
AIM Earnings
On November 17, 2025 AIM reported an EPS of -1.57 and a revenue of 26.00K. The company missed EPS expectations (-59.43% surprise).
AIM Forecast & Estimates
5 analysts have analysed AIM and the average price target is 22.42 USD. This implies a price increase of 2281.81% is expected in the next year compared to the current price of 0.9412.
For the next year, analysts expect an EPS growth of 77.3% and a revenue growth -51.38% for AIM
AIM Groups
Sector & Classification
AIM Financial Highlights
Over the last trailing twelve months AIM reported a non-GAAP Earnings per Share(EPS) of -20.24. The EPS increased by 58.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -391.52% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AIM Ownership
AIM Latest News, Press Relases and Analysis
AIM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 364.65B | ||
| AMGN | AMGEN INC | 15.22 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.56 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.56 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.74 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.51 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.32 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.59 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.33 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AIM
Company Profile
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Company Info
IPO: 1996-07-12
AIM IMMUNOTECH INC
2117 Sw Highway 484
Ocala FLORIDA 34473 US
CEO: Thomas K. Equels
Employees: 21
Phone: 13524487797
AIM IMMUNOTECH INC / AIM FAQ
What does AIM IMMUNOTECH INC do?
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
What is the current price of AIM stock?
The current stock price of AIM is 0.9412 USD. The price increased by 2.53% in the last trading session.
What is the dividend status of AIM IMMUNOTECH INC?
AIM does not pay a dividend.
What is the ChartMill rating of AIM IMMUNOTECH INC stock?
AIM has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for AIM IMMUNOTECH INC?
AIM IMMUNOTECH INC (AIM) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for AIM stock?
AIM IMMUNOTECH INC (AIM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-20.24).